Phase 2 Head and Neck Cancer Trial, Recruiting NCT07061704 Sponsor: Sichuan University Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT07061704
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 80 years old
  • People who have been diagnosed with locally advanced squamous cell carcinoma of the oesophagus (a specific type of oesophageal cancer), with or without cancer that has spread to lymph nodes in the neck
  • People who are able to provide a fresh tumour tissue sample at the start of the trial
  • People whose major organs (such as heart, liver, and kidneys) are functioning normally
  • People with a performance status score of 1 or less — meaning people who are generally able to carry out daily activities with little or no limitation (confirm with trial site)
  • People of childbearing potential who are willing and able to use contraception during the trial
  • People who agree to take part voluntarily and sign a consent form
  • People who are able to follow the trial schedule, attend follow-up appointments, and meet other trial requirements

Who may not be able to join:

  • People who have already received chemotherapy, radiation therapy, or immunotherapy as a previous cancer treatment
  • People considered to be at high risk of gastrointestinal bleeding, a hole in the oesophagus (perforation), or an abnormal connection forming in the oesophagus (fistula)
  • People with poor nutritional status
  • People who experienced serious immune-related side effects (such as severe lung or heart inflammation, graded 3 or higher) during a previous cancer treatment
  • People showing signs or symptoms of interstitial diseases — conditions that affect the tissue and space around the organs, particularly the lungs (confirm with trial site)
  • People with severe or uncontrolled medical conditions
  • People who currently have or have been diagnosed with another type of cancer at the same time
  • People with other autoimmune diseases, or those who have been taking immunosuppressant medications or steroids for an extended period
  • People who have difficulty communicating or who would not be able to attend long-term follow-up appointments
  • People the trial investigators consider unsuitable for other reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +862885422562

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Sichuan University
Registry
ClinicalTrials.gov
Start date
1 August 2025
Est. completion
1 August 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Treatment-related adverse effects (TRAEs); Event Free Survival (EFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov